Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer-Reference-Cited by-同舟云学术

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Published:2016-07-18 Issue:10 Volume:6 Page:1118-1133
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Gainor Justin F.,Dardaei Leila,Yoda Satoshi,Friboulet Luc,Leshchiner Ignaty,Katayama Ryohei,Dagogo-Jack Ibiayi,Gadgeel Shirish,Schultz Katherine,Singh Manrose,Chin Emily,Parks Melissa,Lee Dana,DiCecca Richard H.,Lockerman Elizabeth,Huynh Tiffany,Logan Jennifer,Ritterhouse Lauren L.,Le Long P.,Muniappan Ashok,Digumarthy Subba,Channick Colleen,Keyes Colleen,Getz Gad,Dias-Santagata Dora,Heist Rebecca S.,Lennerz Jochen,Sequist Lecia V.,Benes Cyril H.,Iafrate A. John,Mino-Kenudson Mari,Engelman Jeffrey A.,Shaw Alice T.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 854 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways;Translational Oncology;2024-02

2. Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments;Frontiers in Oncology;2024-01-11

3. ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib;Frontiers in Oncology;2024-01-09

4. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management;Cellular Signalling;2024-01

5. New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer;Phytomedicine;2024-01